Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 11, 2023
In past years, the UK Government has undertaken substantial assessments of each multilateral’s effectiveness to inform UK funding decisions. In this blog, we explore how these major assessments of Value for Money (VfM) affected the UK’s multilateral aid allocation. To do this, we’ve accessed previou...
BRIEFS
June 08, 2023
To meet many of today’s most pressing challenges, we need to find new solutions. But the fastest, cheapest, and most effective way to encourage high-impact innovation isn’t always obvious. Governments, philanthropists, and the private sector typically invest in research and development (R&D) by bett...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 23, 2022
Pull financing is an underutilized tool that can drive the development and adoption of critical technologies necessary to address the globe’s climate crisis. This paper provides tangible examples by presenting two case studies that illustrate how pull climate finance can be used to deliver urgently ...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
November 15, 2022
Congress has excellent legislation on the docket that would protect American citizens, yield huge returns, and create a safer, healthier world. We encourage the US Congress to urgently finance and authorize the PASTEUR Act, leveraging American ingenuity to boost our shared health future.